June 04, 2010 07:00 ET

Mirada Medical demonstrates XD3's Enhanced Quality Control Features

OXFORD, UK--(Marketwire - June 4, 2010) -

                          Mirada Medical Limited
                        ("Mirada" or "the Company")

  Mirada Medical demonstrates XD3's Enhanced Quality Control Features for
                  Accurate SUV Readings of Oncology Scans

Oxford, UK and Ohio, US, 4 June 2010: Mirada Medical Limited, the profitable and fast growing international company focused on advanced oncology imaging announced today that at the forthcoming Society of Nuclear Medicine Conference (5th to 9th June 2010, Salt Lake City) it will highlight comprehensive Standardised Uptake Value (SUV) quality control features for use with its XD3 PET-CT and multi-modal image analysis application.

The Standardised Uptake Value can be used by clinicians to quantify the metabolic activity of a tumour in an FDG-PET or FDG-PET/CT scan. Variations in the SUV may be caused by, amongst other factors, errors or inconsistencies in the scanning procedure and is a recognised problem since such variations cannot be distinguished from those related to changes in the disease. It is important that any such errors or inconsistencies are highlighted to the user as SUV readings can help the clinician assess treatment response and determine the best treatment regimen for oncology patients. Mirada Medical's improved quality control features enable inconsistencies in the input data to be easily recognised by the user. Key data can be tracked across time points to assess the validity of any comparison they may need to make in reporting disease change. Using the quality control features of Mirada's XD3, users can quickly and more reliably spot parameters which may be inconsistent or beyond the range acceptable to the user.

Commenting on today's announcement, Chief Technology Officer, Dr Timor Kadir said: "Clinical users are aware of the limitations and variations which may exist when reporting the activity of a malignancy using an SUV. Mirada have been providing data quality control features in our products for many years and our XD3 application allows users to quickly identify those values or ranges which may be inconsistent or beyond acceptable bounds. The team at Mirada Medical has studied the latest research in designing our improved quality control features to ensure our users can follow current best practice when assessing the quality of the SUV they are reading from the scan."

Mirada Medical will showcase its latest industry leading developments at this year's Society of Nuclear Medicine Annual Conference, held 5-9 June 2010, in Salt Lake City, Utah. Mirada Medical's team will be located at booth No. 1613.

For more information, please contact:

Mirada Medical
Europe: Hugh Bettesworth, CEO
tel: +44 (0) 1865 811172

US: Joan Washburn
tel: +1 865 696 7809

M:Communications
Mary-Jane Elliott / Emma Thompson
tel: +44 (0)20 7920 2345
Healthcare@mcomgroup.com

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with an enhanced software package for the quantification of images, typically used in cancer diagnosis and treatment response assessment. Mirada Medical's technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada's advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient's condition. Mirada's products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world's leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada's products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada- medical.com.

About XD3

Mirada's XD3 multi-modality clinical reading application empowers radiologists and oncologists with the image analysis they need to diagnose diease and assess follow up to treatment. XD3 combines powerful registration technologies with serial review of acquisitions acquired over time. Key product features include disease specific oncology workflows and fast, accurate and reproducible image quantification, Mirada's world class image registration engine powers multi-modal fusion and registration across time. XD3 facilitates advanced clinical decision support and may be deployed on PACS, workstation or laptop, providing the most flexible workflow integration available anywhere. Mirada Medical continues to develop superior products to suit the needs of clinicians for reviewing images in diagnosing, staging and evaluating disease progression and response to therapy. Mirada's XD3 product provides comprehensive levels of analytical power to the clinical user. Featuring powerful disease specific oncology workflows and fast, accurate and reproducible image quantification, XD3 facilitates advanced clinical decision support. XD3 may be deployed on PACS, home workstation or laptop, providing the most productive workflow integration available anywhere.

About Society of Nuclear Medicine (SNM) Annual Conference

The 57th Annual Meeting will take place on June 5-9 2010 at the Salt Palace Convention Center in Salt Lake City, Utah. SNM is an international scientific and professional organization of more than 17,000 physicians, technologists, physicists, chemists and radiopharmacists dedicated to improving health care by advancing molecular imaging and therapy. The meeting features more than 1,600 scientific papers and posters submitted by scientists, physicians and technologists in the molecular imaging and nuclear medicine fields. In addition, more than 170 manufacturers attend the meeting to showcase and demonstrate the most technologically advanced molecular imaging and nuclear medicine equipment.

[HUG#1421548]